Investment
Features
FeesSafety
Academy
More
Pluang+

Compare FormFactor Inc. FormFactor Inc. Common Stock (FORM) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

FormFactor Inc. FormFactor Inc. Common StockTrade
Inovio Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

FormFactor Inc. FormFactor Inc. Common Stock vs Inovio Pharmaceuticals Inc — how do they compare? FormFactor Inc. FormFactor Inc. Common Stock trades at $139.67 (market cap $10.71B), while Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M). The key difference: FormFactor Inc. FormFactor Inc. Common Stock is far larger — about 95.5× Inovio Pharmaceuticals Inc's market cap, and FormFactor Inc. FormFactor Inc. Common Stock is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold FormFactor Inc. FormFactor Inc. Common Stock for 1 Days and Inovio Pharmaceuticals Inc for 43 Days on average.

FORMINO
Market Cap
$10.71B$112.19M
Volume
1,680,4253,201,278
Sector
TechnologyHealth
52-Week High
$159.93$2.65
52-Week Low
$38.14$0.66
Typical Hold Time
1 Days43 Days
Enterprise Value
$10.40B$83.51M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

FormFactor Inc. FormFactor Inc. Common Stock

No Aura AI signal available yet.

Inovio Pharmaceuticals Inc

INO Pharmaceuticals trades at $1.09, down 5.63% today, with a bearish technical outlook despite positive analyst sentiment. The company faces significant fundamental challenges with minimal revenue of $65,340 in 2025 and substantial losses of $84.95 million. Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis, which could transform the company's prospects if approved.

Investment outlook hinges on FDA approval of INO-3107, with analysts maintaining a $2.75 consensus target representing 152% upside. However, persistent cash burn and negative profitability metrics pose substantial risks. The stock offers high-risk, high-reward potential for investors comfortable with binary regulatory outcomes in biotech.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

FORM

No sentiment data available yet.

INO
96% Buy4% Sell
Avg holding period · 43 Days

About FormFactor Inc. FormFactor Inc. Common Stock

FormFactor, Inc. provides semiconductor test and measurement technologies used across the integrated circuit lifecycle, manufacturing probe cards and analytical probes through its Probe Cards segment and probe stations, thermal systems, and cryogenic systems through its Systems segment.

Read more on FORM →

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO →